Skip to main content

Advertisement

SpringerLink
Log in

Clinical significance of performing 18F-FDG PET on patients with gastrointestinal stromal tumors: a summary of a Japanese multicenter study

  • Original Article
  • Published:
Annals of Nuclear Medicine Aims and scope Submit manuscript

Abstract

Objective

The aim of this study is to evaluate the clinical significance of performing 18F-fluorodeoxyglucose (FDG) positron-emission tomography (PET) on patients with gastrointestinal stromal tumors (GISTs).

Methods

The patient samples for this study were provided by seven PET institutions in Japan. Forty-one patients with pathologically proved GISTs, 24 men and 17 women (mean age 60.3 years, range 26–81 years) were enrolled in this study. Final diagnosis was based on the follow-up imaging at least 3 months after the PET scan or histopathological examinations.

Results

There were eight preoperative cases and 33 follow-up cases in our series. Preoperative cases showed that the sites of primary tumor were the stomach (5 cases, 62.5%), and small intestine (3 cases, 37.5%). One stomach lesion and one small intestine lesion showed negative findings. In follow-up cases, there were 18 PET-negative cases. Among them, two cases were considered as false negative by follow-up imaging. On the other hand, 15 cases showed positive findings at 23 lesions. Most PET-positive cases were considered as true positive except for one false-positive case, who later received surgery and was diagnosed as leiomyoma histopathologically. In 14 cases, PET findings were considered to provide additional information to conventional imaging. In eight cases among them, PET findings were considered to have influenced the decision-making of therapeutic plans.

Conclusion

Our data suggest that FDG PET has an incremental value over conventional imaging for the diagnostic and therapeutic management of patients with GISTs in Japan as reported worldwide, and supports its introduction as a routine diagnostic tool for patients with GISTs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Miettinen M, Lasota J. Gastrointestinal stromal tumors—definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch. 2001;438:1–12.

    Article  PubMed  CAS  Google Scholar 

  2. Corless CL, Fletcher JA, Heinrich MC. Biology of gastrointestinal stromal tumors. J Clin Oncol. 2004;22:3813–25.

    Article  PubMed  CAS  Google Scholar 

  3. Rosai J. Gastrointestinal tract. In: Rosai J, Ewing J, editors. Ackerman’s surgical pathology. St Louis: Mosby Year-Book; 1996. p. 645–6932.

    Google Scholar 

  4. Hasegawa T, Matsuno Y, Shimoda T, Hirohashi S. Gastrointestinal stromal tumor: Consistent CD117 immunostaining for diagnosis, and prognostic classification based on tumor size and MIB-1 grade. Hum Pathol. 2002;33:669–76.

    Article  PubMed  Google Scholar 

  5. Taniguchi M, Nishida T, Hirota S, Isozaki K, Ito T, Nomura T, et al. Effect of c-kit mutation on prognosis of gastrointestinal stromal tumors. Cancer Res. 1999;59:4297–300.

    PubMed  CAS  Google Scholar 

  6. DeMatteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg. 2000;231:51–8.

    Article  PubMed  CAS  Google Scholar 

  7. Van den Abbeele AD. The lessons of GIST–PET and PET/CT: a new paradigm for imaging. Oncologist. 2008;13 Suppl 2:8–13.

    Article  PubMed  Google Scholar 

  8. Stroobants S, Goeminne J, Seegers M, Dimitrijevic S, Dupont P, Nuyts J, et al. 18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Gleevec). Eur J Cancer. 2003;39:2012–20.

    Article  PubMed  CAS  Google Scholar 

  9. Antoch G, Kanja J, Bauer S, Kuehl H, Renzing-Koehler K, Schuette J, et al. Comparison of PET, CT, and dual-modality PET/CT imaging for monitoring of imatinib (STI-571) therapy in patients with gastrointestinal stromal tumors. J Nucl Med. 2004;45:357–65.

    PubMed  CAS  Google Scholar 

  10. Van den Abbeele A, Badawi R, Cliche J, Janicek M, Tetrault R, Spangler T, et al. 18F-FDG-PET predicts response to imatinib mesylate (Gleevec) in patients with advanced gastrointestinal stromal tumors (GIST). Proc Am Soc Clin Oncol. 2002;21a:403a. abstr 1610.

    Google Scholar 

  11. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205–16.

    Article  PubMed  CAS  Google Scholar 

  12. Gold JS, Dematteo RP. Combined surgical and molecular therapy: the gastrointestinal stromal tumor model. Ann Surg. 2006;244:176–84.

    Article  PubMed  Google Scholar 

  13. Raut CP, Morgan JA, Ashley SW. Current issues in gastrointestinal stromal tumors: incidence, molecular biology, and contemporary treatment of localized and advanced disease. Curr Opin Gastroenterol. 2009;23:149–58.

    Article  Google Scholar 

  14. Richter KK, Schmid C, Thompson-Fawcett M, Settmacher U, Altendorf-Hofmann A. Long-term follow-up in 54 surgically treated patients with gastrointestinal stromal tumours. Langenbecks Arch Surg. 2008;393:949–55.

    Article  PubMed  Google Scholar 

  15. Fletcher CD, Berman JJ, Corless C, Gorstein F, Lasota J, Longley BJ, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol. 2002;33:459–65.

    Article  PubMed  Google Scholar 

  16. Yamada M, Niwa Y, Matsuura T, Miyahara R, Ohashi A, Maeda O, et al. Gastric GIST malignancy evaluated by 18FDG-PET as compared with EUS-FNA and endoscopic biopsy. Scand J Gastroenterol. 2007;42:633–41.

    Article  PubMed  Google Scholar 

  17. Kamiyama Y, Aihara R, Nakabayashi T, Mochiki E, Asao T, Kuwano H, et al. 18F-fluorodeoxyglucose positron emission tomography: useful technique for predicting malignant potential of gastrointestinal stromal tumors. World J Surg. 2005;29:1429–35.

    Article  PubMed  Google Scholar 

  18. Blay JY, Bonvalot S, Casali P, Choi H, Debiec-Richter M, Dei Tos AP, et al. GIST consensus meeting panelists. Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20–21 March 2004, under the auspices of ESMO. Ann Oncol. 2005;16:566–78.

    Article  PubMed  Google Scholar 

  19. Ng EH, Pollock RE, Romsdahl MM. Prognostic implications of patterns of failure for gastrointestinal leiomyosarcomas. Cancer. 1992;69:1334–41.

    Article  PubMed  CAS  Google Scholar 

  20. Gayed I, Vu T, Iyer R, Johnson M, Macapinlac H, Swanston N, et al. The role of 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors. J Nucl Med. 2004;45:17–21.

    PubMed  CAS  Google Scholar 

  21. Meirelles GS, Ravizzini G, Yeung HW, Akhurst T. Esophageal leiomyoma: a rare cause of false-positive FDG scans. Clin Nucl Med. 2006;31:342–4.

    Article  PubMed  Google Scholar 

  22. Joensuu H, Roberts PJ, Sarlomo-Rikala M, Andersson LC, Tervahartiala P, Tuveson D, et al. Effect of the tyrosine kinase inhibitor STI-571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med. 2001;344:1052–6.

    Article  PubMed  CAS  Google Scholar 

  23. Pietras K, Ostman A, Sjoquist M, Buchdunger E, Reed RK, Heldin CH, et al. Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors. Cancer Res. 2001;61:2929–34.

    PubMed  CAS  Google Scholar 

  24. Buchdunger E, Zimmermann J, Mett H, Meyer T, Müller M, Druker BJ, et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res. 1996;56:100–4.

    PubMed  CAS  Google Scholar 

  25. Oetzel C, Jonuleit T, Gotz A, van der Kuip H, Michels H, Duyster J, et al. The tyrosine kinase inhibitor CGP 57148 (STI-571) induces apoptosis in BCR-ABL-positive cells by down-regulating BCL-X. Clin Cancer Res. 2000;6:1958–68.

    PubMed  CAS  Google Scholar 

  26. Van den Abbeele AD, Badawi RD. Use of positron emission tomography in oncology and its potential role to assess response to imatinib mesylate therapy in gastrointestinal stromal tumors (GISTs). Eur J Cancer. 2002;38(suppl 5):S60–5.

    PubMed  Google Scholar 

  27. Holdsworth CH, Badawi RD, Manola JB, Kijewski MF, Israel DA, Demetri GD, et al. CT and PET: early prognostic indicators of response to imatinib mesylate in patients with gastrointestinal stromal tumor. Am J Roentgenol. 2007;189:W324–30.

    Article  Google Scholar 

  28. Bechtold R, Chen M, Stanton TA, Savage PD, Levine EA. Cystic changes in hepatic and peritoneal metastases from gastrointestinal stromal tumors treated with Gleevec. Abdom Imaging. 2003;28:808–14.

    Article  PubMed  CAS  Google Scholar 

  29. Blay JY, Le Cesne A, Ray-Coquard I, Bui B, Duffaud F, Delbaldo C, et al. Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group. J Clin Oncol. 2007;25:1107–13.

    Article  PubMed  CAS  Google Scholar 

  30. Choi H, Charnsangavej C, Faria SC, Tamm EP, Benjamin RS, Johnson MM, et al. CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG-PET findings. Am J Roentgenol. 2004;183:1619–28.

    Google Scholar 

  31. Choi H, Charnsangavej C, Faria SC, Macapinlac HA, Burgess MA, Patel SR, et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol. 2007;25:1753–9.

    Article  PubMed  Google Scholar 

Download references

Acknowledgment

This work was supported in part by the Grant-in-Aid for Cancer Research (17-12) from the Ministry of Health, Labour and Welfare, Japan.

Author information

Authors and Affiliations

  1. Department of Diagnostic Radiology, Tohoku University Graduate School of Medicine, Sendai, Japan

    Tomohiro Kaneta & Shoki Takahashi

  2. Department of Nuclear Medicine and Radiology, Institute of Development, Aging and Cancer, Tohoku University, 4-1 Seiryocho, Aoba-ku, Sendai, 980-8575, Japan

    Hiroshi Fukuda

  3. Department of Diagnostic Radiology and Nuclear Medicine, Gunma University Graduate School of Medicine, Maebashi, Japan

    Yukiko Arisaka & Noboru Oriuchi

  4. Radiology Division, National Cancer Center Hospital East, Chiba, Japan

    Takayuki Hayashi

  5. Functional Imaging Division, National Cancer Center Hospital East, Chiba, Japan

    Hirofumi Fujii

  6. Division of Cancer Screening, Research Center for Cancer Prevention and Screening, National Cancer Center, Tokyo, Japan

    Takashi Terauchi

  7. Department of Radiology, Yokohama City University School of Medicine, Yokohama, Japan

    Ukihide Tateishi

  8. Division of Nuclear Medicine, Department of Radiology, International Medical Center of Japan, Tokyo, Japan

    Kazuo Kubota

  9. Department of Diagnostic Imaging and Nuclear Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan

    Tadashi Hara & Yuji Nakamoto

  10. PET Center, Dokkyo Medical University, Tochigi, Japan

    Kazuhiro Kitajima & Koji Murakami

Authors
  1. Tomohiro Kaneta
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shoki Takahashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hiroshi Fukuda
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yukiko Arisaka
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Noboru Oriuchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Takayuki Hayashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Hirofumi Fujii
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Takashi Terauchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Ukihide Tateishi
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Kazuo Kubota
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Tadashi Hara
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Yuji Nakamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Kazuhiro Kitajima
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Koji Murakami
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hiroshi Fukuda.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kaneta, T., Takahashi, S., Fukuda, H. et al. Clinical significance of performing 18F-FDG PET on patients with gastrointestinal stromal tumors: a summary of a Japanese multicenter study. Ann Nucl Med 23, 459–464 (2009). https://doi.org/10.1007/s12149-009-0257-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12149-009-0257-1

Keywords

Search

Navigation